Gram-negative infections (GNIs) represent a high-value segment of the antibiotic market and are often treated in the hospital setting. Infections due to Gram-negative pathogens (GNPs) are…
Last Updated 12 September 2014 The type 2 diabetes therapy market will rapidly expand over our 2013-2023 study period, fueled by the disease’s increasing prevalence and a high unmet need for…
Crohn’s disease (CD) and ulcerative colitis (UC) are two gastrointestinal autoimmune/inflammatory indications that commonly feature treatment with biological therapies. The U.S. CD market…
Pulmonary hypertension (PH) is a devastating disease, for which there is no cure. Despite the rarity of the disease, the potential commercial rewards from drugs approved for it are considerable,…
With approximately two-thirds of peripheral arterial disease (PAD) patients being asymptomatic, drug treatment for PAD patients focuses largely on the symptomatic patients who have either…
Psoriatic arthritis (PsA) is a disease hallmarked by psoriatic skin lesions and erosive joint damage that remains poorly understood, underdiagnosed, and undertreated. Nevertheless, tumor necrosis-…
Diabetic retinopathy (DR) is characterized by progressive damage to the blood vessels in the retina of a diabetic patient, from which fluid may leak causing the macula to swell. Swelling of the…
Muscular dystrophy (MD) is associated with degeneration and weakness of affected muscles that vary with the type of dystrophy. Dystrophies are characterized by common histological features such as…
This three-wave LaunchTrends report series will track the post-launch awareness, trial, and usage of Anoro Ellipta among pulmonologists for the treatment of chronic obstructive pulmonary disease (…
Population health management (PHM) represents one of the long-term goals of the healthcare industry: building upon the patient-centered medical home concept to provide proactive support to a…
Glaucoma refers to a group of chronic, progressive eye diseases caused primarily by elevated intraocular pressure (IOP) resulting from the blockage or decreased drainage of the aqueous humor…
Improvements in patient access to novel treatments for chronic obstructive pulmonary disease (COPD) in Brazil and Mexico are largely dependent on the expansion of drug coverage by local authorities…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma. The first-generation protease inhibitors were a major advancement in the…
As the pharmaceutical pipeline begins to churn out specialty products at a higher rate than traditional therapies, the nation’s healthcare payers are experiencing double-digit growth in their…
Currently available therapies for the treatment of Ankylosing Spondylitis (AS) target primarily the signs and symptoms of the disease; scant data exist demonstrating an impact on structural…